In a final appraisal determination, the National Institute of Health and Clinical Excellence recommended Eli Lilly and Daiichi Sankyo’s Efient (prasugrel) for use on the NHS as a treatment to prevent atherothrombotic events in certain high-risk patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI).

[ad]

NICE stated that the antiplatelet agent, in combination with aspirin, should only be used when immediate primary PCI for myocardial infarction is necessary, stent thrombosis has occurred during treatment with sanofi-aventis and Bristol-Myers Squibb’s Plavix (clopidogrel), or if the patient has diabetes.

Efient was launched in the UK earlier this year.

Source: FirstWord

Popularity: 5% [?]